Compare Citius Pharmaceuticals Inc (CTXR) vs Fastly Inc (FSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Fastly Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Fastly Inc trades at $29.3 (market cap $4.03B). The key difference: Fastly Inc is far larger — about 295.9× Citius Pharmaceuticals Inc's market cap, and Fastly Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Fastly Inc for 26 Days on average.
| CTXR | FSLY | |
|---|---|---|
Market Cap | $13.62M | $4.03B |
Volume | 132,438 | 5,516,495 |
Sector | Health | Technology |
52-Week High | $1.82 | $33.50 |
52-Week Low | $0.48 | $7.86 |
Typical Hold Time | 17 Days | 26 Days |
Enterprise Value | $3.79M | $4.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Fastly (FSLY) trades at $25.29, showing minimal daily movement (+0.04%) with neutral technical indicators. The company has demonstrated strong revenue growth, reaching $624 million in 2025, and has beaten earnings expectations for three consecutive quarters. However, profitability remains a concern with negative net income margins (-11.8%) and ROE (-8.39%). Recent insider selling by the CTO and CEO has created some investor uncertainty despite positive AI-related business developments.
The outlook for FSLY is cautiously optimistic with analyst consensus pointing to 12% upside to the $28.25 price target. Key opportunities include AI-driven edge computing demand and revenue growth trajectory toward $1.1-1.3 billion by 2029. Major risks include persistent profitability challenges, competitive pressure in cloud infrastructure, and execution risks in achieving long-term targets amid insider selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
